Could an allergy pill tame gut inflammation?

NCT ID NCT07333716

Recruiting now Disease control Sponsor: Tanta University Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is testing whether adding the allergy medicine desloratadine to standard ulcerative colitis treatment can better control inflammation and symptoms. About 44 adults with mild to moderate ulcerative colitis will take either desloratadine plus mesalamine or mesalamine alone for three months. Researchers will measure changes in disease activity and blood markers of inflammation.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: desloratadine
What this could lead to: If it works, this could point toward a simple, low-cost add-on treatment to better control ulcerative colitis symptoms and inflammation.
What could go wrong: This is a small, early-phase trial with only 44 participants, so results may not apply widely. The benefit over standard therapy alone is uncertain, and desloratadine may cause side effects like drowsiness or dry mouth.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ULCERATIVE COLITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ulcerative colitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ULCERATIVE COLITIS ULCERATIVE COLITIS (UC)

Contacts and locations

Locations

Menofia university Hospitals
RECRUITING

Shibīn al Kawm, Menofia, 32511, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.